Martinez D A, King D R, Ginn-Pease M E, Haase G M, Wiener E S
Department of Surgery, Ohio State University College of Medicine, Columbus.
J Pediatr Surg. 1992 Aug;27(8):1016-20; discussion 1020-1. doi: 10.1016/0022-3468(92)90549-m.
Current recommendations for treatment of children with IV-S neuroblastoma (NB) indicate that "supportive care is the cornerstone of therapy" and resection of the primary tumor is not mandated. The presentation and clinical management of 37 IV-S NB patients from three pediatric oncology centers were retrospectively reviewed. The 22 boys and 15 girls presented at an average age of 107 days (range, 4 to 616 days). Primary tumor sites were identified in the adrenal gland in 19 children, the thorax in 5, the retroperitoneum in 4, and 1 each in the pelvis and kidney. At the time of presentation, metastatic disease was documented in the liver (27), bone marrow (19), skin (7), and regional lymph nodes (7). Massive hepatomegaly (below the umbilicus) was demonstrated in 18 patients. Twenty-eight children (76%) have survived on average 90 months following diagnosis. Eight patients (22%) died; six of disease and two of complications of therapy (mean, 9.6 months). One child was lost to follow-up. Only 3 of the 37 patients (8%) were managed solely by supportive care and all are alive. Extirpation of the primary tumor was accomplished in 24 individuals (65%). Twenty patients underwent excision at diagnosis and four had delayed resection with few postoperative complications and no deaths related to resection. One death resulted from progression of disease in a child who had tumor removal. Chemotherapy as a single treatment or in combination with radiation was used in 10 children with three children surviving (30%).(ABSTRACT TRUNCATED AT 250 WORDS)
目前针对IV-S期神经母细胞瘤(NB)患儿的治疗建议表明,“支持性治疗是治疗的基石”,不强制要求切除原发肿瘤。回顾性分析了来自三个儿科肿瘤中心的37例IV-S期NB患者的临床表现及临床管理情况。22例男孩和15例女孩的平均就诊年龄为107天(范围4至616天)。19例患儿的原发肿瘤位于肾上腺,5例位于胸部,4例位于腹膜后,骨盆和肾脏各1例。就诊时,有肝转移(27例)、骨髓转移(19例)、皮肤转移(7例)及区域淋巴结转移(7例)的记录。18例患者出现肝脏肿大(脐下)。28例患儿(76%)在确诊后平均存活了90个月。8例患者(22%)死亡,其中6例死于疾病,2例死于治疗并发症(平均9.6个月)。1例患儿失访。37例患者中仅3例(8%)仅接受支持性治疗,且均存活。24例患者(65%)成功切除了原发肿瘤。20例患者在确诊时接受了切除手术,4例延迟切除,术后并发症少,无切除相关死亡病例。1例肿瘤切除患儿因疾病进展死亡。10例患儿接受了单纯化疗或化疗联合放疗,3例存活(30%)。(摘要截选至250词)